-+ 0.00%
-+ 0.00%
-+ 0.00%
Novartis failed an advanced trial for a muscle disorder disease, and the stock prices of some pharmaceutical company developers fell. SAREPTA THERAPEUTICS fell 11.4% and DYNE THERAPEUTICS fell 22%.
Share
Listen to the news
Novartis failed an advanced trial for a muscle disorder disease, and the stock prices of some pharmaceutical company developers fell. SAREPTA THERAPEUTICS fell 11.4% and DYNE THERAPEUTICS fell 22%.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending